Klinikum Wels-Grieskirchen GmbH

Klinikum Wels‑Grieskirchen is conducting studies in breast cancer, focusing on early‑stage hormone‑receptor‑positive disease as well as advanced HER2‑negative and HER2‑positive subtypes. Trials aim to test new targeted agents, improve adjuvant therapy, and assess combination regimens to enhance survival.

• Adjuvant CDK4/6 inhibition
• Combination of HER2‑targeted therapy with chemotherapy
• Neoadjuvant endocrine strategies
• Biomarker‑driven treatment selection

These efforts reflect the site’s commitment to advancing personalized oncology care for women in Austria.

Research at the site includes extensive work on non‑small cell lung cancer (NSCLC) and extensive‑stage small‑cell lung cancer, investigating novel immunotherapies, KRAS‑targeted agents, and high‑PD‑L1 strategies. The goal is to improve progression‑free survival and overall survival for patients with advanced disease.

• KRAS G12C inhibitors
• PD‑L1 based immunotherapy combinations
• First‑line chemo‑immunotherapy regimens
• Biomarker‑guided patient selection

Klinikum Wels‑Grieskirchen collaborates with international partners to bring cutting‑edge lung cancer trials to the region.

The department focuses on multiple myeloma, diffuse large B‑cell lymphoma, acute myeloid leukemia, and myelodysplastic syndromes. Trials evaluate novel antibody‑drug conjugates, combination regimens, and maintenance strategies to deepen responses and extend remission.

• Anti‑BCMA therapies
• R‑CHOP enhancements for high‑risk DLBCL
• Venetoclax‑based regimens for MDS
• MRD‑guided treatment adaptation

With 20 investigators, the site offers patients access to state‑of‑the‑art hematology trials.

Studies target immune thrombocytopenia, generalized myasthenia gravis, ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis. Objectives include evaluating new biologics, assessing disease‑modifying potential, and improving quality of life.

• Anti‑FcRn antibodies for ITP
• IL‑5 pathway blockade in EoE
• Combination biologics for inflammatory bowel disease
• Novel agents for myasthenia gravis

These trials reflect the department’s immunology expertise within the hospital setting.

Clinical work addresses transthyretin amyloid cardiomyopathy, polycythemia vera, and non‑alcoholic steatohepatitis (NASH). The purpose is to test disease‑modifying drugs that reduce cardiac deposition, control hematologic proliferation, and resolve liver fibrosis.

• TTR stabilizers for ATTR‑CM
• JAK2 inhibitors in polycythemia vera
• FXR agonists for NASH
• Metabolic pathway modulators

The site’s multidisciplinary approach links cardiology, hepatology, and hematology for integrated patient care.

Research includes chronic kidney disease with albuminuria and progressive pulmonary fibrosis such as idiopathic pulmonary fibrosis and PF‑ILDs. Trials aim to preserve renal function, slow lung function decline, and improve patient‑reported outcomes.

• Selective endothelin antagonists for CKD
• Anti‑fibrotic agents in IPF
• Combination therapies for PF‑ILD
• Biomarker assessment of disease progression

Klinikum Wels‑Grieskirchen provides a platform for patients to access emerging therapies in these high‑need areas.

The institution investigates colorectal cancer, pancreatic ductal adenocarcinoma, gastric stromal tumors, and rare solid neoplasms. Objectives focus on targeted combinations, chemotherapy optimization, and novel immunotherapies to increase response rates.

• HER2‑targeted therapy in colorectal cancer
• PARP inhibition in pancreatic cancer
• TKI approaches for GIST
• Immunotherapy in rare solid tumors

These programs expand therapeutic options for patients with challenging gastrointestinal malignancies.